AuXin Surgery Announces the Launch of its new CADISS System for Selective Dissection in Surgery

February 7, 2019 News Turnstone Communications

Louvain-la-Neuve, Belgium, 7 February 2019 – AuXin Surgery, a medical device company, announces that it has obtained CE Class III certification for its novel CADISS® System for the surgery of chronic otitis and epidural fibrosis.

The CADISS® System is a selective dissection device based on the combination of irrigated surgical instruments with the topical application of a chemical solution adapted to surgery. The chemical solution selectively cleaves the disulfide bonds responsible for the adhesion of pathological tissues and for the mechanical strength of fibrosis. The device is expected to facilitate critical dissection steps where there is a risk of damaging organs such as nerves, veins or muscles, or leave pathologic material in the body. Originally invented by surgeons, it addresses an unmet need and an extension to additional indications has been applied for.

The CADISS® System is the first commercially available system of chemically assisted surgery. The benefits are supported by investigatory clinical trials involving more than 900 patients in 8 representative indications.

Gilles Capart, founder and CEO comments: “I am glad that this very useful invention is finally made available to surgeons, to facilitate critical dissections and reduce the risks of side effects for their patients.”

About the CADISS® System

The CADISS® System is supplied as kits containing the single use sterile elements including the Drug Product and the fluid lines. The reusable irrigated surgical instruments adapted to the intended uses are supplied separately.
The CADISS System will be distributed initially in Belgium, The Netherlands, Luxemburg, Italy, United Kingdom, Germany, Austria, Switzerland, Spain and Portugal, with additional countries to follow.

About AuXin Surgery

AuXin Surgery is the pioneer in chemically assisted dissection. The method was invented originally by the team of ENT surgeons of the University of Parma, Italy, under the leading of Prof. Carlo Zini. The company was incorporated in January 2014 to develop medical devices and make this method available to surgeons in their regular practice. The development has been funded in part by grants from the Walloon Region. For more information about CADISS and AuXin Surgery, please visit www.auxin.eu.

Contact
AuXin Surgery
info@auxin.eu
+32 10 39 22 18


Turnstone Communications
Turnstone Communications

We are a specialized consultancy agency providing communications, marketing and strategic support to companies and organizations in the life sciences industry. We share client articles on BioVox providing insight into new and established players in the Belgian ecosystem, from innovations and research breakthroughs through to finance and industry trends.

All posts